SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-23-000061
Filing Date
2023-05-25
Accepted
2023-05-25 16:09:24
Documents
13
Period of Report
2023-05-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20230523.htm   iXBRL 8-K 56449
  Complete submission text file 0001599298-23-000061.txt   226039

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20230523.xsd EX-101.SCH 2159
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20230523_def.xml EX-101.DEF 15283
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20230523_lab.xml EX-101.LAB 29621
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20230523_pre.xml EX-101.PRE 15940
7 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20230523_htm.xml XML 11117
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 23960530
SIC: 2834 Pharmaceutical Preparations